A Breakthrough in Diabetes Treatment: 25-Year-Old Woman Stops Insulin Thanks to an Innovative Transplant
In a world-first in regenerative medicine, a 25-year-old woman with type 1 diabetes was able to stop taking insulin thanks to a pioneering transplant of pancreatic islets derived from induced pluripotent stem (iPS) cells. This revolutionary procedure marks a significant advance in the fight against diabetes, a disease that affects millions of people worldwide.
The patient, who lives in Tianjin, shared her incredible experience in an interview with Nature: “I can finally eat sugar. It’s been over a year since the transplant, and now I enjoy all kinds of food, especially hotpot.” For privacy reasons, she chose to remain anonymous.
Dr. James Shapiro, a transplant surgeon and researcher at the University of Alberta in Canada, described the results as “extraordinary”: “The patient’s diabetes has been completely reversed. Previously, she required large amounts of insulin daily.”
The study, published in the journal Cell, adds to other successful research in the field. Notably, a team in Shanghai recently reported the case of a 59-year-old man with type 2 diabetes who, after a similar transplant, was able to stop using insulin.
Diabetes is a chronic disease that affects nearly half a billion people worldwide. In type 1 diabetes, the immune system attacks the beta cells of the pancreas, preventing the production of insulin, the hormone that regulates blood sugar levels. While pancreatic islet transplants can help control the disease, the shortage of donors and the need for immunosuppressive drugs to prevent rejection remain significant obstacles.
Induced pluripotent stem (iPS) cells, on the other hand, offer a potentially limitless solution. They are obtained from the patient’s own cells, reprogrammed in the laboratory to return to a primitive state, and then transformed into pancreatic islets capable of producing insulin. This method eliminates the risk of rejection, since the transplanted cells originate from the patient’s own body.
The research team led by Dr. Deng Hongkui at Peking University used cells collected from three patients with type 1 diabetes, reprogramming them in the laboratory to return to a pluripotent state. Two and a half months after the procedure, the patient began producing enough insulin to live without injections. After more than a year, her blood glucose levels stabilized, remaining within a safe range 98% of the time.
“This is a remarkable outcome,” commented Daisuke Yabe, a diabetes researcher at Kyoto University. “If these results can be replicated in other patients, it would represent a huge step forward.”
Although the results are promising, experts caution that further studies with a larger sample size will be necessary.
Dr. Deng confirmed that the other two participants in the trial also showed positive results and plans to extend the study to an additional 10–20 patients.
This innovation offers new hope for millions of people living with diabetes, bringing us closer to the goal of an effective, personalized regenerative therapy capable of transforming the lives of those affected by this chronic disease.
Source: